Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | August 26, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date August 26, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-26 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-26 · Exercise / conversion · Acquired 30,000 · Balance 30,000 Row 2 · 2026-08-26 · Tax withholding · Disposed 3,315 · Balance 26,685 F1: These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein. Row 3 · 2026-08-26 · Sale · Disposed 26,685 · Balance 0 F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.49 · Expires 2029-09-17 | Direct | 30,000 |
Reported balance
After 2026-08-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-26 · Exercise / conversion · Disposed 30,000 · Balance 30,000 F3: Fully exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3: Fully exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Aug 28, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $13.49 | $0.00 |
DisclosureSEC source: 0001193125-26-374607 · ownership.xml · derivative · entry 4 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 26,685 | $122.55 | $3,270,169.36 |
DisclosureSEC source: 0001193125-26-374607 · ownership.xml · nonDerivative · entry 3 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 3,315 | $122.09 | $404,728.35 |
DisclosureSEC source: 0001193125-26-374607 · ownership.xml · nonDerivative · entry 2 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,685 F1 · kind: These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 30,000 | $13.49 | $404,700.00 |
DisclosureSEC source: 0001193125-26-374607 · ownership.xml · nonDerivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2026 Filed May 26, 2026 21:28 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $59.69 | $0.00 |
DisclosureSEC source: 0001193125-26-239683 · ownership.xml · derivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-21 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:44 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0000950170-25-085763 · ownership.xml · derivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $28.09 | $0.00 |
DisclosureSEC source: 0000950170-24-063202 · ownership.xml · derivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-16 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 17, 2024 over a one-year period. Read SEC document |
| May 19, 2023 Filed May 23, 2023 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $24.10 | $0.00 |
DisclosureSEC source: 0000899243-23-013736 · doc4.xml · derivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 19, 2023 over a one-year period. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $20.84 | $0.00 |
DisclosureSEC source: 0000899243-22-020698 · doc4.xml · derivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-30 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 31, 2022 over a one-year period. Read SEC document |
| May 26, 2021 Filed May 28, 2021 21:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $21.45 | $0.00 |
DisclosureSEC source: 0000899243-21-021134 · doc4.xml · derivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 26, 2021 over a one-year period. Read SEC document |
| May 27, 2020 Filed May 29, 2020 23:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0000899243-20-014622 · doc4.xml · derivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-26 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 27, 2020 over a one-year period. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 21:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $13.49 | $0.00 |
DisclosureSEC source: 0000899243-19-023845 · doc4.xml · derivative · entry 1 Park Kimberly · CIK 0001788208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-09-17 F1 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable with respect to 25% of the shares on the first anniversary of the date of grant and, thereafter, at the rate of 2.08334% of the total number of shares per month, until fully vested and exercisable on the fourth anniversary of the date of grant, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.